stoxline Quote Chart Rank Option Currency Glossary
  
Allarity Therapeutics, Inc. (ALLR)
0.1865  -0.018 (-8.58%)    07-18 16:00
Open: 0.2001
High: 0.204
Volume: 4,630,234
  
Pre. Close: 0.204
Low: 0.184
Market Cap: 5(M)
Technical analysis
2024-07-18 3:48:47 PM
Short term     
Mid term     
Targets 6-month :  0.46 1-year :  0.61
Resists First :  0.39 Second :  0.52
Pivot price 0.2
Supports First :  0.18 Second :  0.15
MAs MA(5) :  0.19 MA(20) :  0.23
MA(100) :  2.62 MA(250) :  12.03
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  19.3 D(3) :  16
RSI RSI(14): 19.7
52-week High :  69 Low :  0.18
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ALLR ] has closed above bottom band by 3.7%. Bollinger Bands are 97.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 53 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.25 - 0.25 0.25 - 0.25
Low: 0.19 - 0.19 0.19 - 0.19
Close: 0.2 - 0.2 0.2 - 0.21
Company Description

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 12 Jul 2024
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Significant Increase in Short Interest - Defense World

Mon, 24 Jun 2024
Why Allarity Therapeutics (ALLR) Stock Is Getting Hammered - Benzinga

Thu, 06 Jun 2024
Allarity Therapeutics Signs New Management Services Agreement - TipRanks

Tue, 07 May 2024
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock | ALLR Stock News - StockTitan

Tue, 07 May 2024
Allarity Therapeutics Announces that All Series A Preferred - GlobeNewswire

Tue, 07 May 2024
All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 26 (M)
Held by Insiders 1.761e+007 (%)
Held by Institutions 0 (%)
Shares Short 469 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 2
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -89.7 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -6.54444e+007
Qtrly Earnings Growth 32.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio 0.09
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.01
Stock Dividends
Dividend 0
Forward Dividend 1.04e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android